ALLERGY THERAPEUTICS PLC

Remuneration Information • Nov 5, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1591W

Allergy Therapeutics PLC

05 November 2014

5 November 2014

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

Grant of Options

Allergy Therapeutics plc (AIM: AGY) announces that, pursuant to the Allergy Therapeutics plc Long Term Share Incentive Plan ('LTIP'), on 5 November 2014 provisional shares of 0.1 pence each in the share capital of the Company were awarded to the following Board Directors: Mr Manuel Llobet (Chief Executive Officer) and Mr Ian Postlethwaite (Finance Director) at nil cost, as follows:

Director	Number of provisional shares awarded	Date of distribution	Total provisional shares held under LTIPs
Manuel Llobet	845,000	4 November 2014	3,315,000
Ian Postlethwaite	422,500	4 November 2014	1,657,500

The issuance and distribution of ordinary shares of 0.1 pence each under the LTIP is conditional on the Company's performance over the course of three years.  The new Long Term Incentive Plan was adopted by the Board on 20 March 2013.

-Ends-

For further information

Allergy Therapeutics	+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
www.allergytherapeutics.com
Peel Hunt LLP	+44 (0) 20 7418 8900
James Steel / Clare Terlouw
FTI Consulting	+44 (0) 20 3727 1000
Simon Conway/ Mo Noonan / Victoria Foster Mitchell

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination.  It has a growing business with revenue of £42million achieved mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBIBDBCXGBGSS